IP Library Granted Patent US 10,479,993
Granted Patent B2
US 10,479,993 · App. 15/149,642 · Granted Nov 19, 2019

Modulation of signal transducer and activator of transcription 3 (STAT3) expression

Inventors: Eric E. Swayze (Carlsbad, CA); Susan M. Freier (Carlsbad, CA); Robert A. MacLeod (Carlsbad, CA); Youngsoo Kim (Carlsbad, CA)
Assignee: Ionis Pharmaceuticals, Inc.
C12N15/113C07H21/00C07H21/04C12N15/00C12N15/11C12N15/1135C12N2310/11C12N2310/315C12N2310/3231C12N2310/3341C12N2310/341C12N2310/346C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,993
App. No.
15/149,642
Granted
Nov 19, 2019
Kind
B2
Abstract

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

Claims (10)

1. A compound comprising a sodium salt of a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 245, and comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5′ wing segment consisting of 3 linked nucleosides; and

a 3′ wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine.

2. A compound comprising a potassium salt of a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 245 and comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5′ wing segment consisting of 3 linked nucleosides; and

a 3′ wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: SWAYZE, ERIC E; FREIER, SUSAN M; MACLEOD, ROBERT A; KIM, YOUNGSOO
To: IONIS PHARMACEUTIALS, INC.
Reel/Frame 049752/0060 →
CHANGE OF NAME Recorded Sep 7, 2016
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 040026/0460 →
Continuity (9)
Continuation 14338880 · Jul 23, 2014
Continuation 13436558 · Mar 30, 2012
Provisional Application 61558316 · Nov 10, 2011
Provisional Application 61558308 · Nov 10, 2011
Provisional Application 61471045 · Apr 1, 2011
Provisional Application 61147035 · Apr 1, 2011
Provisional Application 61471015 · Apr 1, 2011
Provisional Application 61471001 · Apr 1, 2011
Related Publication 20160348104A1 · Dec 1, 2016